Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) reported on Wednesday the availability of Atomoxetine Capsules, USP in the US market.
In addition, the company's Atomoxetine Capsules, USP is available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg with 30 counts bottle size. Atomoxetine is used to treat attention-deficit hyperactivity disorder (ADHD), including psychological, social, and other treatments. It may help to increase the ability to pay attention, concentrate, stay focused and stop fidgeting.
The company said the US Food and Drug Administration (USFDA) approved Atomoxetine Capsules, USP, is the therapeutic equivalent generic version of Strattera (atomoxetine) Capsules. Straterra is a registered trademark of Eli Lilly and Company.
For the most recent 12 months ending in August 2018, the Strattera brand and generic had US sales of about USD304m MAT, according to IMS Health.
Amneal to unveil generic Isoproterenol Hydrochloride Injection USP in the US
Amneal passes US FDA approval for marketing Carmustine for Injection USP in 100 mg/vial
Mylan launches Medroxyprogesterone Acetate Injectable Suspension USP in US
Dr Reddy's Laboratories to divest Hyderabad API manufacturing business unit to Therapiva Private
Dr. Reddy's Laboratories divests API manufacturing business unit in Jeedimetla, Hyderabad, India
Breckenridge awarded US FDA approval for Roflumilast Tablets (Daliresp) ANDA
ANI Pharmaceuticals launches Candesartan Hydrochlorothiazide Tablets
Dr. Reddy's Laboratories Has Regained Worldwide Rights to DFA-02
Dr. Reddy's Laboratories Launches Imatinib Mesylate Tablets, USP in the US Market